C4 Therapeutics, Inc.
CCCC
$4.26
-$0.14-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -15.00% | 112.79% | -26.90% | -46.17% | 138.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.00% | 112.79% | -26.90% | -46.17% | 138.17% |
| Cost of Revenue | -55.10% | -7.16% | -18.37% | 10.29% | -88.51% |
| Gross Profit | 7.31% | 14.89% | 10.42% | -67.99% | 123.85% |
| SG&A Expenses | 0.01% | -11.51% | -24.20% | -9.57% | -9.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.77% | -20.34% | -19.94% | 4.53% | 10.91% |
| Operating Income | 4.73% | 38.62% | 16.16% | -32.92% | 2.08% |
| Income Before Tax | 4.53% | 40.87% | -30.41% | -46.87% | 7.19% |
| Income Tax Expenses | -- | -7.63% | -- | -- | -- |
| Earnings from Continuing Operations | 4.53% | 40.75% | -30.41% | -46.87% | 7.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.53% | 40.75% | -30.41% | -46.87% | 7.19% |
| EBIT | 4.73% | 38.62% | 16.16% | -32.92% | 2.08% |
| EBITDA | 4.62% | 38.98% | 16.48% | -32.83% | 2.13% |
| EPS Basic | 46.37% | 64.18% | -25.12% | -42.29% | 10.33% |
| Normalized Basic EPS | 46.36% | 63.87% | 16.62% | -28.53% | 1.90% |
| EPS Diluted | 46.37% | 64.18% | -25.12% | -42.29% | 10.33% |
| Normalized Diluted EPS | 46.36% | 63.87% | 16.62% | -28.53% | 1.90% |
| Average Basic Shares Outstanding | 77.99% | 65.40% | 4.22% | 3.19% | 3.51% |
| Average Diluted Shares Outstanding | 77.99% | 65.40% | 4.22% | 3.19% | 3.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |